Balyasny Asset Management
GYRE icon

Balyasny Asset Management’s Gyre Therapeutics GYRE Stock Holding History

Balyasny Asset Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,979
Closed -$244K – 2775
2024
Q1 		$244K Buy
+13,979
New +$252K ﹤0.01% 2333

Other funds holding GYRE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Balyasny Asset Management's GYRE Position: Q2 2024 in Review

Balyasny Asset Management sold out of Gyre Therapeutics (GYRE) in Q2 2024, closing a stake of 13,979 shares — an estimated $244K sold.

Balyasny Asset Management first reported a position in GYRE in Q1 2024 and held it in 1 quarter. The position peaked at $244K in Q1 2024. 30 funds tracked by Wall St. Rank hold GYRE as of Q2 2024.

  • Balyasny Asset Management reported no remaining Gyre Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 13,979 Gyre Therapeutics shares in Q2 2024, an estimated $244K.
  • Balyasny Asset Management first reported a position in Gyre Therapeutics in Q1 2024 and held it in 1 quarter.
  • Balyasny Asset Management's Gyre Therapeutics position peaked at $244K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.